Review article · 2026 · Open access
Towards clinical translation of nanomedicines: Formulation scale-up and model systems
Advanced Drug Delivery Reviews, 234, 115862 · Published 31 March 2026 · DOI 10.1016/j.addr.2026.115862
In brief
“Towards clinical translation of nanomedicines: Formulation scale-up and model systems” is a 2026 review article by Owen M. Kelly and 12 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 27 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Advanced Drug Delivery Reviews.
- Citations
- 27
- Most cited in
- 2026 (27)
- Field-weighted impact
- 8.46
- References
- 231
- Authors
- 13
Abstract
Non-viral nanomedicines, including nanoparticles (NPs) composed of lipids and polymers, represent a transformative approach to drug and gene therapy. However, clinical translation of these technologies is limited by two key barriers: the scale-up of NP formulations and the challenge of conducting predictive preclinical studies in relevant animal models. Efficient upscaling of nanomedicines, from cost and material requirement perspectives, requires manufacturing processes that can reliably provide products across the many orders of magnitude of scale from discovery (kg of product). Additionally, initial preclinical studies are often performed in mouse models for discovery; however, mid- to large-size animal models such as rabbits, pigs, sheep, and nonhuman primates are more relevant to human scale and physiology in the context of evaluating the safety, efficiency, and efficacy of therapeutic strategies proposed for use in humans across age groups. This review summarizes some current strategies to scale-up the production of nanomedicines for translational investigations. Animal models and new approach methodologies are also addressed for NP assessment and screening, including the physiological distinctions when comparing rodent models to larger species that can impact NP delivery. Current challenges are also highlighted in terms of scale-up and preclinical validation with the objective of highlighting scalable, effective nanomedicine platforms that can be considered for translation to human trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kelly, O. M., Hanna, A. R., Byrne, A. K., Green, J. A., Périssé, I. V., Wells, K. D., Murray, S. A., Xu, J., Chen, Y. E., Polejaeva, I. A., Tarantal, A. F., Issadore, D., & Piotrowski-Daspit, A. S. (2026). Towards clinical translation of nanomedicines: Formulation scale-up and model systems. Advanced Drug Delivery Reviews, 234, 115862. https://doi.org/10.1016/j.addr.2026.115862
MLA 9
Kelly, Owen M., et al. “Towards clinical translation of nanomedicines: Formulation scale-up and model systems.” Advanced Drug Delivery Reviews, vol. 234, 2026, p. 115862. https://doi.org/10.1016/j.addr.2026.115862.
Chicago
Kelly, Owen M., Andrew R. Hanna, Addison K. Byrne, Jonathan A. Green, Iuri Viótti Périssé, Kevin Dale Wells, Stephen A. Murray, et al. 2026. “Towards clinical translation of nanomedicines: Formulation scale-up and model systems.” Advanced Drug Delivery Reviews 234: 115862. https://doi.org/10.1016/j.addr.2026.115862.
Harvard
Kelly, O. M. et al. (2026) ‘Towards clinical translation of nanomedicines: Formulation scale-up and model systems’, Advanced Drug Delivery Reviews, 234, p. 115862. doi:10.1016/j.addr.2026.115862.
IEEE
O. M. Kelly et al., “Towards clinical translation of nanomedicines: Formulation scale-up and model systems,” Advanced Drug Delivery Reviews, vol. 234, p. 115862, 2026, doi: 10.1016/j.addr.2026.115862.
BibTeX
@article{kelly2026towards,
title = {{Towards clinical translation of nanomedicines: Formulation scale-up and model systems}},
author = {Kelly, Owen M. and Hanna, Andrew R. and Byrne, Addison K. and Green, Jonathan A. and Périssé, Iuri Viótti and Wells, Kevin Dale and Murray, Stephen A. and Xu, Jie and Chen, Y. Eugene and Polejaeva, Irina A. and Tarantal, Alice F. and Issadore, David and Piotrowski-Daspit, Alexandra S.},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {234},
pages = {115862},
doi = {10.1016/j.addr.2026.115862},
url = {https://doi.org/10.1016/j.addr.2026.115862}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- nanomedicine
- clinical translation
- lipid nanoparticles
- polymeric nanoparticles
- large animal model
- preclinical validation
- new approach methodologies
- nanoparticle delivery
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Kelly, O. M., Hanna, A. R., Byrne, A. K., Green, J. A., Périssé, I. V., Wells, K. D., Murray, S. A., Xu, J., Chen, Y. E., Polejaeva, I. A., Tarantal, A. F., Issadore, D., & Piotrowski-Daspit, A. S. (2026). Towards clinical translation of nanomedicines: Formulation scale-up and model systems. Advanced Drug Delivery Reviews, 234, 115862. https://doi.org/10.1016/j.addr.2026.115862
How many times has this paper been cited?
27 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.
Who wrote this paper?
Owen M. Kelly, Andrew R. Hanna, Addison K. Byrne, Jonathan A. Green, Iuri Viótti Périssé, Kevin Dale Wells, Stephen A. Murray, Jie Xu, Y. Eugene Chen, Irina A. Polejaeva, Alice F. Tarantal, David Issadore and 1 more.
What is the DOI of this paper?
10.1016/j.addr.2026.115862, permanently at https://doi.org/10.1016/j.addr.2026.115862. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.